Dietrich A. Stephan, Ph.D.
Chairman & Chief Executive Officer, Founder
Dr. Stephan is an industry veteran who is considered one of the fathers of the field of precision medicine, having trained with the leadership of the Human Genome Project at the NIH and then going on to lead discovery research at the Translational Genomics Research Institute and serve as professor and chairman of the Department of Human Genetics at the University of Pittsburgh. Stephan has identified the molecular basis of dozens of genetic diseases and published extensively in journals such as Science, the New England Journal of Medicine, Nature Genetics, PNAS and Cell. In parallel, Dr. Stephan has founded or co-founded 14 biotechnology companies and has advised an additional 12 companies. These companies are backed by the top-tier investors such as Sequoia Capital, KPCB, Thiel Capital, and Khosla Ventures as well as corporate partners such as Life Technologies, Pfizer, and Mayo Clinic. Dr. Stephan received his Ph.D. from the University of Pittsburgh and his BS from Carnegie Mellon University.
Dov Goldstein, M.D., M.B.A.
Dr. Goldstein brings to the NeuBase board of directors more than two decades of experience in the biopharmaceutical industry as a venture capital investor, an executive and a member of the boards of directors of a number of successful companies including ADMA Biologics (ADMA), Cempra Pharmaceuticals (CEMP), Durata Therapeutics, Esperion Therapeutics (ESPR), and Loxo Oncology (LOXO). The companies where Dr. Goldstein has played a leadership role have resulted in the approval of 2 drugs: Eraxis (anidulafungin) and Dalvance (dalbavancin). Dr. Goldstein was the chief financial officer of Schrödinger, LLC from 2017 to 2018. Dr. Goldstein served as a Managing Partner at Aisling Capital, a healthcare dedicated private investment firm, from 2014 to October 2017, Partner from 2008 to 2014 and a Principal at Aisling Capital from 2006 to 2008. Dr. Goldstein served as the chief financial officer of Loxo Oncology, Inc. between July 2014 and January 2015, and was its acting chief financial officer from January 2015 to May 2015. From 2000 to 2005, Dr. Goldstein served as chief financial officer of Vicuron Pharmaceuticals, Inc., which was acquired by Pfizer, Inc. in September 2005, and helped lead the M&A process. Prior to joining Vicuron, Dr. Goldstein was director of venture analysis at HealthCare Ventures. Dr. Goldstein serves as a director and chairman of the compensation committee of ADMA Biologics, Inc. (Nasdaq: ADMA). He serves as a director and member of the audit committee of Esperion Therapeutics. Dr. Goldstein received a B.S. from Stanford University, an MBA from Columbia Business School and an M.D. from Yale School of Medicine.
Gerald J. McDougall
Mr. McDougall spent almost his entire career as a senior partner at PwC where he built and led the firm's Global Health Science consulting practice before retiring. He has worked across the entire ecosystem of the healthcare industry and advised an array of Fortune 500 companies, including leading global pharmaceutical companies. Mr. McDougall has been instrumental around the globe in building public-private partnerships to address human health imperatives. These include the creation and maturation of the Translational Genomics Research Institute (TGen), Arizona's renowned bio-cluster; the design and launch of the Multiple Myeloma Research Consortium (MMRC); the strategic plan for the California Institute of Regenerative Medicine (CIRM) and the Country of Luxemburg's biotechnology commercialization ecosystem.
Diego Miralles, M.D.
Dr. Diego Miralles brings successful drug development expertise at both large and early-stage pharmaceutical companies to the board of NeuBase. Dr. Miralles is the chief executive officer of Vividion Therapeutics, Inc., a biotechnology company with a platform to discover and develop small molecule therapeutics. Prior to Vividion, Dr. Miralles had an extensive career at Johnson & Johnson, culminating in his position as the Global Head of Innovation and a member of the management committee of Janssen. He started his career at Johnson & Johnson at Tibotec BVBA, a leading virology company where he was a member of the management board and was involved in the development and approval of PREZISTA® and INTELENCE®. He was the head of the Janssen Research and Early Development unit in La Jolla, CA. While at Johnson & Johnson, he founded and launched the JLABS incubator for start-up life science entrepreneurs, and was instrumental in developing and launching Johnson & Johnson’s Innovation center model. Prior to Johnson & Johnson, Dr. Miralles held R&D positions at Trimeris, Inc. and Triangle Pharmaceuticals, Inc., and he was an assistant professor at Duke University Medical Center, where he was a bench scientist and an infectious disease physician, with a focus on HIV. He received his M.D. degree from the Universidad de Buenos Aires, Argentina, completed his internal medicine residency at the Mayo Clinic and was a fellow in Infectious Diseases at Cornell University-New York Hospital.
Franklyn Prendergast, M.D., Ph.D.
Dr. Franklyn Prendergast brings decades of significant experience to Neubase, in addition to his scientific expertise in peptide nucleic acids, membrane biochemistry and oncology. Currently, Dr. Prendergast is the chairman of the board of directors of the Infectious Disease Research Institute and serves on the boards of several start-up companies. Previously, Dr. Prendergast was a member of the board of directors of Eli Lilly & Co. from 1995 to 2017 while simultaneously serving as a director of the Mayo Clinic Cancer Center. He has also held several additional positions at the Mayo Clinic, including as a member of the board of governors and the board of trustees, as the director of the Mayo Clinic Center for Individualized Medicine and as the Emeritus Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and an Emeritus Professor of Molecular Pharmacology and Experimental Therapeutics at the Mayo Medical School. He was named a Mayo Clinic Distinguished Investigator in 1989. Throughout his career, Dr. Prendergast has served with the NIH on a number of grant review groups and advisory committees, including as a member of the board of advisors for the Division of Research Grants and on the National Advisory General Medical Sciences Council. In addition to these positions, Dr. Prendergast held a Presidential Commission for service on the National Cancer Advisory Board. Dr. Prendergast obtained his M.D. degree from the University of West Indies and attended Oxford University as a Rhodes Scholar, earning an M.A. degree in Physiology. He obtained his Ph.D. in Biochemistry at the University of Minnesota.
Eric Richman, M.B.A.
Mr. Richman brings experience in investing in and operating early stage biotech companies. He was involved with the development and launch of several orphan drugs including CytoGam®, Synagis®, Cinryzeâ, Ethyolâ, Respigamâ, and others and has decades of experience at PharmAthene, MedImmune and Tyrogenex. Currently, Mr. Richman is the interim chief executive officer of LabConnect, Inc., a provider of global central laboratory services, a position he has held since November 2018. Mr. Richman was previously a venture partner at Brace Pharma Capital, a life science venture capital firm, from January 2016 to September 2018 and is involved with several private and public biotechnology companies. He served as chief executive officer of Tyrogenex Inc., a biopharmaceutical company, from 2016 to 2018. Mr. Richman served as the president and chief executive officer of PharmAthene, Inc., subsequently acquired by Altimmune, Inc., between October 2010 and March 2015. He also served on PharmAthene’s board of directors, when the company was listed on the NYSE, from 2010 to 2017. Prior to joining PharmAthene, Mr. Richman was a member of the founding team of MedImmune, where he held various commercial and strategic positions, including director of international commercialization. In addition, he has served as a member of numerous boards of directors. Mr. Richman currently serves as a director of Adma Biologics, Inc. (Nasdaq: ADMA), including audit, compensation and governance and nominating committees; Variant Pharmaceuticals, Inc.; NovelStem International Corp. (OTCMKTS: NSTM); and LabConnect, Inc. where he serves as the chairman of the board. Mr. Richman has also served as a director of Lev Pharmaceuticals, Inc. and as chairman of its commercialization committee, and served as a director of American Bank Incorporated (acquired by Viropharma). Mr. Richman received a B.S. in Biomedical Science from the Sophie Davis School of Biomedical Education (CUNY Medical School) and a M.B.A. from the American Graduate School of International Management.